WALVAX(SZ:300142) 合成生物学与绿色生物制造·2026-02-24 03:14Core Viewpoint - Watson Bio has established a 1 billion yuan investment fund focused on synthetic biology and related industries, aiming to enhance investment efficiency and align with national bio-economy development plans [2][3]. Investment Fund Details - The Yunnan Chuangwo Biological Industry Investment Fund has a target size of 1 billion yuan, with Watson Bio contributing 450 million yuan, representing 45% of the fund [2]. - The fund will focus on various sectors within synthetic biology, including enzyme preparations, amino acids, probiotics, plant extraction, recombinant collagen, and bio-agriculture [3]. Company Background - Watson Bio, founded in 2001, specializes in the research, development, production, and sales of biological pharmaceuticals, particularly human vaccines, and was listed on the Shenzhen Stock Exchange in 2010 [5]. Strategic Outlook - The year 2026 is identified as a critical turning point for the company, transitioning from a phase of consolidation to one of performance and valuation growth [6]. - The company’s strategy aligns with the "14th Five-Year Plan," emphasizing support for innovation in the biological manufacturing industry [7]. Financial Performance - In the first three quarters of 2025, Watson Bio reported revenues of 1.719 billion yuan and a net profit attributable to shareholders of 163 million yuan [7].